About ReShape
ReShape is a Healthcare company based in San Clemente (United States) founded in 2005, and was acquired by EnteroMedics in October 2017. A dual intra-gastric balloon system is provided for weight loss. ReShape has raised $90.32 million across 9 funding rounds from investors including SVB, New Leaf Venture Partners and Oxford Finance. Its chief executive, as recorded, is Michael Mangano. ReShape offers products and services including LAP-BAND, ReShape Vest, and ReShape Care. Its focus areas include Life Sciences, Obesity, Medical Devices and Therapeutic Devices. Its legal entity is ReShape Lifesciences Inc. Its competitors include Apollo Endo, USGI Medical and Vibrynt; 3 of its 3 listed competitors have raised funding.
Company details
ReShape Medical has developed the ReShape Dual Balloon, a dual intra-gastric balloon system for weight loss. It is inserted into the stomach through an endoscopic procedure and filled with saline (salt water). The balloons remain in the stomach for six months and help reduce hunger. Insertion of the gastric balloon is completed in about 20 minutes, with no hospital stay required. The company has received FDA approval for its ReShape Integrated Dual Balloon system.
- Headquarters San Clemente, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website reshapeready.com
- Social LinkedIn X Facebook
- Acquired by EnteroMedics (Oct 2017)
- Legal Name Reshape Lifesciences Inc
- Total Equity Funding$90.32M (USD)
in 9 rounds
- Latest Funding Round$11M (USD), Debt – Conventional
Feb 2017
- InvestorsSVB
& 8 more
- Acquired byEnteroMedics
(Oct 2017)
Products & Services of ReShape
ReShape offers a comprehensive portfolio of products and services, including LAP-BAND, ReShape Vest, and ReShape Care.
Minimally invasive device for long-term obesity treatment.
Laparoscopically implanted system for rapid weight loss.
Virtual tele-health coaching for sustained weight management.
Funding Insights of ReShape
ReShape has successfully raised a total of $90.32M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $11 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90.32M
- Total Rounds 9
- Last Round Debt – Conventional — $11M
- First Round $3M
(Aug 2007)
- Investors Count 8
All 9 funding rounds of ReShape with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $11M | Debt – Conventional | – | – | – |
| Aug 2015 | $38M | Series D | – | HealthCor Partners | |
| Apr 2015 | $12M | Debt – Conventional | – | – | |
| Feb 2015 | $6.75M | Series C | – | – | – |
| Dec 2014 | $5.25M | Series C | – | – | – |
| Oct 2012 | $15.82M | Series C | – | USVP, New Leaf Venture Partners | – |
| Jun 2012 | $1.5M | Series C | – | – | – |
| Oct 2008 | $20M | Series B | – | USVP | |
| Aug 2007 | $3M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in ReShape
ReShape has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, New Leaf Venture Partners and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| healthcorpartners.com | ||||
Endeavour Vision is focused on transformative healthcare technology investments. | endeavourvision.com | Geneva, Switzerland | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
VC firm that focuses on early stage investments in the US | usvp.com | Menlo Park, United States | ||
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | ventureinvestors.com | Madison, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Satiety induction through vagal nerve block | 2002 | enteromedics.com | Saint Paul, United States |
Investor details for ReShape
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReShape
1 people are tracked at ReShape (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Mangano | CEO | Leadership |
Complete people profiles for ReShape
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReShape
4 dated milestones of ReShape across 12 years, from founding to its latest funding, stage changes and deals.
- Founded ReShape is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Debt – Conventional, of $11.0M.
- Exit Acquired by EnteroMedics.
Competitors of ReShape
ReShape has 3 listed competitors in our database, 3 of them funded. They include Apollo Endo, USGI Medical and Vibrynt.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| apolloendo.com | 2005 | Austin, United States | $80.36M | 132 | Therapeutic devices for obesity and GI disorders are developed. | |
| usgimedical.com | 2001 | San Clemente, United States | $45.95M | Incisionless operating platform for weight loss surgery | ||
| vibrynt.com | 2006 | Palo Alto, United States | $50.25M | Provides durable coat hooks and storage solutions for home use. |
Detailed competitors of ReShape
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as ReShape (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ReShape
ReShape was founded in 2005 and raised its 1st funding round 2 years after it was founded.
ReShape is headquartered in San Clemente, United States. It is registered at San Clemente, California, United States.
Michael Mangano is the CEO of ReShape, as recorded in our data.
ReShape is a funded company, having raised a total of $90.32M across 9 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Aug 2007.
ReShape Medical has developed the ReShape Dual Balloon, a dual intra-gastric balloon system for weight loss. It is inserted into the stomach through an endoscopic procedure and filled with saline (salt water). The balloons remain in the stomach for six months and help reduce hunger. Insertion of the gastric balloon is completed in about 20 minutes, with no hospital stay required. The company has received FDA approval for its ReShape Integrated Dual Balloon system.
ReShape's top competitors include Apollo Endo, USGI Medical and Vibrynt.
ReShape offers LAP-BAND, ReShape Vest, and ReShape Care.
ReShape has 9 investors. Key investors include SVB, New Leaf Venture Partners, Oxford Finance, EnteroMedics, and HealthCor Partners.
ReShape operates through Reshape Lifesciences Inc.
Yes. ReShape was acquired by EnteroMedics in October 2017.